Tim Kong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3947309/publications.pdf

Version: 2024-02-01

8 papers	397 citations	1307543 7 h-index	1588975 8 g-index
9 all docs	9 docs citations	9 times ranked	662 citing authors

#	Article	IF	Citations
1	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature Communications, 2019, 10, 557.	12.8	125
2	CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer Research, 2020, 80, 444-457.	0.9	88
3	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications, 2019, 10, 558.	12.8	76
4	Direct Binding between Pre-S1 and TRP-like Domains in TRPP Channels Mediates Gating and Functional Regulation by PIP2. Cell Reports, 2018, 22, 1560-1573.	6.4	37
5	Identification and characterization of hydrophobic gate residues in TRP channels. FASEB Journal, 2018, 32, 639-653.	0.5	32
6	eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. Molecular Cancer Therapeutics, 2019, 18, 2158-2170.	4.1	25
7	Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFÎºB pathway inhibition. Blood Advances, 2022, 6, 611-623.	5.2	11
8	DUSP6 Mediates Resistance to JAK2 Inhibition and Drives Myeloproliferative Neoplasm Disease Progression. Blood, 2021, 138, 55-55.	1.4	1